Literature DB >> 27668045

Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure.

Loretta Fala.   

Abstract

Entities:  

Year:  2016        PMID： 27668045      PMCID： PMC5013853     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  6 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  Lifetime costs of medical care after heart failure diagnosis.

Authors:  Shannon M Dunlay; Nilay D Shah; Qian Shi; Bruce Morlan; Holly VanHouten; Kirsten Hall Long; Véronique L Roger
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-12-07

3.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

4.  Ivabradine in stable coronary artery disease without clinical heart failure.

Authors:  Kim Fox; Ian Ford; Philippe Gabriel Steg; Jean-Claude Tardif; Michal Tendera; Roberto Ferrari
Journal:  N Engl J Med       Date:  2014-08-31       Impact factor: 91.245

5.  Hospitalization for congestive heart failure: United States, 2000-2010.

Authors:  Margaret Jean Hall; Shaleah Levant; Carol J DeFrances
Journal:  NCHS Data Brief       Date:  2012-10

6.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.